Medicine company Eli Lilly and Company (NYSE: LLY) announced on Monday that it has received U.S. Food and Drug Administration Breakthrough Therapy designation for olomorasib as a monotherapy for adults with previously treated advanced pancreatic cancer carrying a KRAS G12C mutation.
The designation is based on preliminary results from the Phase 1/2 LOXO-RAS-20001 study evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumours, including pancreatic cancer, and is intended to accelerate the drug's development and regulatory review.
Lilly said there are currently no approved therapies specifically targeting KRAS G12C-mutant pancreatic cancer, a rare form of the disease associated with poor outcomes.
Olomorasib is also being evaluated in multiple clinical studies, including the pivotal SUNRAY-01 and SUNRAY-02 trials in KRAS G12C-mutant non-small cell lung cancer.
Harbour BioMed partner raises USD225m to advance neoadjuvant immuno-oncology therapy porustobart
Kazia Therapeutics doses first patient in paediatric AT/RT study
Fusion Antibodies secures Canadian patent for OptiMAL
Revvity to acquire Human Cell Design to expand metabolic disease drug discovery capabilities
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Orphalan commences Phase 3 study of trientine therapy in Wilson disease
ZAGENO named Frost & Sullivan's 2026 North American Life Sciences E-Commerce Company of the Year
Pharvaris reports Phase 3 success for deucrictibant XR in HAE prophylaxis
Sky Labs presents clinical research outcomes for ring-type blood pressure monitor CART